Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Evommune, Inc.NYSE: EVMN
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $0, compared with $0 a year earlier.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net receivables increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Net Receivables vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 net receivables of $0 is the 9th highest of the 10 companies compared; the peer median is $12.64M.
- Net receivables amounts to 0.0% of total assets for EVMN, versus a peer median of 4.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $654.4M | -11.5% | -16.1% | 24.1% |
| Sep 2026 | $413.86M | +1310.0% | -48.2% | 35.2% | |
| Jun 2026 | $69.92M | +66.0% | +20.3% | 3.2% | |
| Mar 2026 | $23.36M | -33.7% | -17.8% | 17.8% | |
| Mar 2026 | $12.64M | +95.1% | -37.5% | 4.3% | |
| Mar 2026 | $8.03M | -30.7% | -36.0% | 6.2% | |
| Mar 2026 | $1.16M | +161.8% | -65.2% | 0.4% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $600K | -42.0% | +13.5% | 0.6% |
EVMNEvommune, Inc. | Mar 2026 | $0 | — | — | 0.0% |
CLYMClimb Bio, Inc. | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Peer median (excluding EVMN) | $12.64M | -11.5% | -26.9% | 4.3% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.